
Piscataway, NJ, February 12, 2024– Camber Pharmaceuticals is pleased to announce the addition of Paliperidone Extended-Release Tablets to its current portfolio.
Paliperidone Extended- Release Tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia, treatment of schizoaffective disorder as monotherapy, and as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone Extended- Release Tablets are available in 1.5, 3, 6, and 9 mg strengths in 30 count bottles.
To find out more about Paliperidone Extended- Release Tablets please visit www.camberpharma.com/paliperidone
Recent articles
- Camber Launches Temozolomide Capsules, USP
- Camber Launches Eltrombopag Tablets & Oral Suspension
- Camber Launches Eslicarbazepine Acetate Tablets
- Camber Launches Phenylephrine Hydrochloride Injection, USP
- Camber Launches Chlorzoxazone Tablets, USP
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year